Report

The Global Heparin Market size is estimated at USD 9.37 billion in 2024, and is expected to reach USD 13.23 billion by 2029, growing at a CAGR of 7.12% during the forecast period (2024-2029).

The COVID-19 pandemic disrupted not only the research and development of treatments and medications for illnesses other than COVID-19 but also the global supply chain for pharmaceuticals, which in turn had an effect on the market for heparin as well. But numerous research has pointed to the advantages of heparin for COVID-19 patients. For instance, according to an article published by frontiers in August 2020, a large retrospective cohort study was conducted which showed lower mortality in COVID-19 patients treated with heparin. It was also found that patients hospitalized with COVID-19 who received anticoagulation treatment with heparin had a lower risk of mortality, even after adjusting for age and gender, a saturation of oxygen at 90%, temperature greater than 37C, and use of concomitant medications. The heparin market had favorable growth during the early pandemic as a result of this factor. Currently, the market growth has slowed down as the COVID-19 pandemic subsided, and it is expected to have a stagnant growth during the forecast period of the study.

Heparin is a medication that prevents blood clots from forming in patients with specific medical conditions or who are undergoing medical procedures that increase the risk of clot formation, such as surgery. Thus, the rising prevalence of chronic diseases such as cardiovascular disease, cancer, and others, and the attendant demand for more cutting-edge and efficient therapeutics, are anticipated to boost heparin's share of the market and propel its development.

For instance, a research study published by PubMed in February 2021 stated that atrial fibrillation affects 37,574 million people worldwide (0.51 percent of the population) and that its prevalence has increased by 33 percent over the previous 20 years. The study further stated that the burden is greatest in countries with a high socio-demographic index, though the most recent growth has been in countries with a middling socio-demographic index. Additionally, according to the same source, the prevalence of atrial fibrillation could increase globally by more than 60% by 2050, which is anticipated to have a significant impact on the development of the market under study. As a result, the demand for heparin is anticipated to increase, which will propel growth in the heparin market over the study's forecast period. The aging population, especially those over the age of 65, is another factor that is anticipated to have a significant impact on the growth of the heparin market. Long hospital stays, surgeries, and trauma can all increase the likelihood of developing a blood clot, so with an aging population, the studied market is expected to experience significant growth. For instance, the United Nations' World Population Ageing Highlight 2020 report found that the global geriatric population is growing quickly and that, in 2020, there were about 727 million people worldwide who were 65 or older, accounting for about 9.3 percent of the world's population overall. The same report also predicted that by the year 2050, there would be about 1.5 billion people in this age group, representing about a third of the world's population. Therefore, the aging population will have a big impact on the researched market's growth through time and fuel the heparin market's expansion.

In addition, new product launches and strategic activities by major players in the market are positively affecting the growth of the studied market. For example, in January 2022, Ginkgo Bioworks and Optimvia teamed up to improve the manufacturing efficiency of non-animal-derived heparin that are commonly used as an anticoagulant to help prevent blood clots. Hence, the product launches by key market players are expected to boost the market growth during the forecast period of the study.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the side effects of heparin and the emergence of new and advanced oral coagulants may restrain the growth of the heparin market during the forecast period of the study.

Heparin Market Trends

Low Molecular Weight Heparin (LMWH) is Expected to Hold a Significant Share in the Heparin Market During the Forecast Period

Anticoagulant low molecular weight heparin (LMWH) is given intravenously or subcutaneously. For example, dalteparin and enoxaparin, among others, work by activating antithrombin III, which subsequently inactivates thrombin and factor Xa to produce its activity. Low Molecular Weight Heparin (LMWH) is approved by the British National Formulary (BNF), and the National Institute for Health and Care Excellence (NICE) stated that LMWHs can be used to treat deep vein thrombosis (DVT) prophylaxis in medium and high-risk groups (surgical, orthopedic, and medical patients), venous thromboembolism in pregnancy, DVT and pulmonary embolism (PE) in non-pregnant women. Due to the widespread use of LMWH across the world, the LMWH market sector is anticipated to account for a sizable portion of the research market.

Furthermore, the rising geriatric population is also expected to boost segment growth as LMWH has various applications for elderly people. For instance, according to an article published by PubMed Central in December 2021, low molecular weight heparin (LMWH) is widely used and it is recommended by a European guideline for elderly patients with renal failure or during the perioperative period of the knee or hip replacement with no restrictions on specific types.

The firms are continually engaged in developing and marketing new medicines due to the growing burden of chronic diseases, which is further predicted to boost growth in the LMWH segment throughout the study's forecast period. For instance, in August 2022, FDA approved Momenta Pharmaceuticals, Inc.'s M-Enoxaparin product. Together with Sandoz, the generics arm of Novartis AG, Momenta is creating M-Enoxaparin, a technology-enhanced generic version of lovenox. Similarly, in May 2021, Dr. Reddy's Laboratories Ltd. launched Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial upon receiving approval from the FDA. Therefore, due to the abovementioned factors, it is anticipated that during the study's projected period, the low molecular weight heparin segment will hold a sizable market share.

North America is Expected to Occupy a Significant Share in the Heparin Market During the Forecast Period

The North American region is expected to hold a significant share in the heparin market owing to the high burden of chronic diseases in the region, the presence of advanced and robust healthcare infrastructure, the growing geriatric population, and other factors. For instance, according to the data published by the World Bank in 2022, the population aged 65 and above as a percentage of the total population increased in the United States from 16.6% in 2020 to 17% in 2021, and the population aged 65 and above increased in Canada as well from 18.1% in 2020 to 18.6% in 2021.

Moreover, due to the high and rising prevalence of chronic diseases like cancer and cardiovascular diseases, the presence of important market players, and the country's expanding geriatric population, the United States is anticipated to hold a significant share of the studied market in the North American region. For example, according to the Center for Disease Control and Prevention's (CDC) April 2022 update, the exact number of people in the country suffering from deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, but it is estimated that up to 900,000 people in the United States are affected by DVT/PE each year. Additionally, according to the same source, 60,000 to 100,000 Americans per year pass away from DVT/PE. As a result of the high incidence and mortality of DVT/PE, it is anticipated that the use of heparin in treatment procedures will increase, which will spur growth in the heparin market in the United States.

The United States heparin market is also anticipated to grow as a result of the rising number of product approvals in the nation as well as recent advancements. For instance, in February 2022, CD Bioparticles, a top manufacturer and provider of diverse drug delivery goods and services, launched several Heparin products, including Heparin Biotin, Heparin Amine, and Heparin Thiol, and made them available to support drug delivery research. Therefore, as a result of the aforementioned factors, the North American region is estimated to hold a sizable proportion of the worldwide heparin market, with the United States being the largest country within it during the study's forecast period.

Heparin Industry Overview

The heparin market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known. Some of the key companies include Aspen Pharmacare Holdings Limited, B Braun Melsungen AG, Baxter International Inc., Dr. Reddy's Laboratories, Hebei Changshan Biochemical Pharmaceutical, Leo Pharma AS, Opocrin SpA, Pfizer Inc, FRESENIUS KABI, GLAND PHARMA, HIKMA PHARMACEUTICALS, Techdow USA, Viatris Inc., Novartis AG, and Smiths Medical among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format


• 3 months of analyst support